Latest News and Press Releases

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic...

Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net...

INHALE-3 clinical trial in patients living with type 1 diabetes fully enrolled. Will evaluate inhaled insulin (with basal insulin) vs. usual care.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial...

Patent covers compositions of clofazimine, and methods for treating lung infectionsDevelopment of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial...

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...

Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial...

Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Time-in-range during waking...